Patents by Inventor Sudhir V. Shah
Sudhir V. Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130210861Abstract: Methods of treating cardiovascular disease in patients predisposed to or afflicted with kidney disease, particularly chronic kidney disease, are described. In such methods, therapeutically effective amounts of chloroquine-based compounds, for example, hydroxychloroquine, are administered to prevent or otherwise ameliorate arthrosclerosis and other cardiovascular diseases.Type: ApplicationFiled: December 9, 2012Publication date: August 15, 2013Inventors: Ashutosh M. SHUKLA, Sudhir V. SHAH
-
Publication number: 20120053212Abstract: A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or reduce the severity of kidney disease consequent to the acute renal failure.Type: ApplicationFiled: March 29, 2011Publication date: March 1, 2012Applicant: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 7722858Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.Type: GrantFiled: February 9, 2006Date of Patent: May 25, 2010Assignees: Board of Trustees of the University of Arkansas, The United States of America as represented by the Department of Veterans AffairsInventors: Sudhir V. Shah, Alexei G. Basnakian, Yousri M. Barri
-
Patent number: 7476551Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.Type: GrantFiled: August 27, 2002Date of Patent: January 13, 2009Assignee: The Board of Trustees of the University of ArkansasInventors: Yousri M. Barri, Sudhir V. Shah, Alexei G. Basnakian
-
Publication number: 20080293779Abstract: A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or reduce the severity of kidney disease consequent to the acute renal failure.Type: ApplicationFiled: January 28, 2008Publication date: November 27, 2008Applicant: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Publication number: 20080138440Abstract: The present invention relates to novel methods of treating or reducing the likelihood of developing gadolinium toxicity by administering to a patient a metal chelator before, concurrently with, or after exposure to gadolinium. The novel methods comprise, inter alia, the use of iron chelators to aid patients at increased risk of developing a gadolinium-induced condition, such as nephrogenic systemic fibrosis, acute kidney injury, cardiovascular disease and accelerated senescence.Type: ApplicationFiled: November 28, 2007Publication date: June 12, 2008Applicant: CorMedix Inc.Inventors: Sundararaman Swaminathan, Sudhir V. Shah
-
Patent number: 7235542Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 26, 2006Date of Patent: June 26, 2007Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 7045282Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 6, 2005Date of Patent: May 16, 2006Assignee: Shiva Biomedical LLCInventor: Sudhir V. Shah
-
Patent number: 7037643Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 6, 2005Date of Patent: May 2, 2006Assignee: Shiva Biomedicals, LLCInventor: Sudhir V. Shah
-
Patent number: 6998396Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 8, 2004Date of Patent: February 14, 2006Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 6995152Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 8, 2004Date of Patent: February 7, 2006Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 6933104Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: April 20, 2000Date of Patent: August 23, 2005Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 6908733Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: December 9, 2003Date of Patent: June 21, 2005Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 6906052Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: GrantFiled: December 9, 2003Date of Patent: June 14, 2005Assignee: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Publication number: 20040192663Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: ApplicationFiled: April 8, 2004Publication date: September 30, 2004Applicant: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Publication number: 20040121422Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: ApplicationFiled: December 9, 2003Publication date: June 24, 2004Applicant: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Publication number: 20040116401Abstract: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.Type: ApplicationFiled: December 9, 2003Publication date: June 17, 2004Applicant: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Publication number: 20040014772Abstract: Compositions and methods for treating a glomerular disorder. Compositions and methods comprise a cytochrome P450 inhibitor. Preferred inhibitors inhibit a cytochrome P450 2B family member. Compositions and methods reduce proteinuria associated with a glomerular disorder, such as, minimal change nephrotic syndrome.Type: ApplicationFiled: March 10, 2003Publication date: January 22, 2004Inventors: Sudhir V. Shah, Radhakrishna Baliga
-
Publication number: 20030045004Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of:treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.Type: ApplicationFiled: August 27, 2002Publication date: March 6, 2003Inventors: Yousri M. Barri, Sudhir V. Shah, Alexei G. Basnakian
-
Publication number: 20020183333Abstract: Compositions and methods for chemotherapy are disclosed. The compositions and methods disclose herein are effective inhibitors of chemotherapy-induced nephrotoxicity, yet unexpectedly do not inhibit the antineoplastic activity of the chemotherapeutic compound. The chemotherapeutic compositions and methods of the invention comprise an inhibitor of catalytic iron. In a preferred embodiment, the inhibitor is a cytochrome P450 inhibitor and the chemotherapeutic compound is cisplatin.Type: ApplicationFiled: March 19, 2002Publication date: December 5, 2002Inventors: Sudhir V. Shah, Radhakrishna Baliga